Advertisement
ALGN vs IDXX
Which Stock Would AI Choose? Align Technology (ALGN) vs. IDEXX Laboratories (IDXX) Stock Comparison
Key Takeaways
- ALGN is a consumer-leaning dental/orthodontic play driven by Invisalign volume, while IDXX is a recurring-revenue animal health diagnostics franchise.
- Both stocks sit in the healthcare sector, but their demand drivers and risk profiles differ materially.
- IDXX has shown steadier execution with double-digit earnings growth and margin expansion; ALGN faces softer consumer demand and recent analyst downgrades.
- IDXX commands a far larger market capitalization and a higher earnings multiple, reflecting its premium growth profile.
- Analysts still rate both stocks favorably overall, but sentiment has cooled noticeably on ALGN in recent weeks.
Introduction
Align Technology and IDEXX Laboratories both operate in healthcare but target very different end markets. This stock comparison is useful for investors weighing a discretionary, consumer-sensitive medical device name against a steadier, subscription-like diagnostics business. Because ALGN leans on elective orthodontic spending while IDXX rides recurring veterinary testing demand, their relative performance offers a clear lens on risk appetite, growth quality, and market positioning across the current environment.
ALGN Overview and Recent Performance
Align Technology designs and sells the Invisalign clear aligner system, along with iTero intraoral scanners and related digital dentistry services. Its revenue mix is dominated by clear aligners, making the business sensitive to consumer discretionary spending on elective dental procedures.
In recent market activity, ALGN has traded well below its 52-week highs. The company reported record Invisalign case volume in its most recent quarter, with clear aligner revenue growing at a high-single-digit pace, but its imaging and scanner segment has weakened as dental practices defer capital equipment purchases. Net income declined in the same period, and management's full-year outlook points to only low-single-digit revenue growth. This softer demand backdrop has prompted several sell-side firms to lower price targets or trim ratings, citing a weakening consumer environment. A favorable patent-infringement ruling against a competitor was a positive offset, but sentiment has generally turned more cautious in recent weeks.
IDXX Overview and Recent Performance
IDEXX Laboratories is a global leader in veterinary diagnostics, providing instruments, consumables, reference laboratory services, and practice software for companion animal care, along with water and livestock testing. Its recurring consumables and services model generates comparatively predictable revenue.
In recent quarters, IDXX has delivered roughly double-digit revenue growth and even faster earnings-per-share growth, supported by higher diagnostic utilization and expanding gross and operating margins. The company raised its full-year earnings guidance and continues to roll out newer platforms, including its inVue Dx analyzer and Cancer Dx offering. One ongoing headwind is softness in U.S. veterinary clinical visits, particularly wellness visits, which has tempered the growth rate. Even so, the franchise's recurring revenue base, international expansion, and product pipeline have kept analyst sentiment broadly constructive, with several firms reiterating positive ratings in recent weeks.
Trending AI Robots
For traders seeking a data-driven edge, Tickeron's Trending AI Robots page curates a selection of AI trading bots chosen for their suitability to current market conditions. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of tickers, but only a subset earns placement in this featured section. These bots vary widely in trading style, strategy, timeframe, statistical performance, and the sets of tickers they follow — so the page serves as a filtered view of the strongest-performing candidates rather than the full catalog. Exploring the Trending AI Robots section can help investors identify algorithmic approaches aligned with their own timeframe and risk preferences.
Head-to-Head Comparison
The clearest contrast between the two is demand visibility. IDXX earns much of its revenue from recurring diagnostic consumables and reference lab testing, giving it steadier, more predictable cash flows. ALGN, by comparison, depends more heavily on consumers committing to elective orthodontic treatment, which is more exposed to macroeconomic softness and consumer confidence.
Growth and margin trends also diverge. IDXX has been expanding operating margin toward the mid-30s percent range while raising guidance, whereas ALGN is managing a weaker capital-equipment segment and guiding to modest top-line growth. On valuation, IDXX trades at a notably higher earnings multiple and carries a much larger market capitalization, reflecting investors' willingness to pay for its recurring model. Risk factors differ too: ALGN faces consumer-spending and competitive pressures, while IDXX contends with softer U.S. veterinary visit trends and foreign-exchange exposure.
Tickeron AI Verdict
Based on observable factors — trend consistency, stability, catalysts, and relative positioning — Tickeron's AI would likely lean toward IDXX in the current environment. Its recurring revenue base, expanding margins, upward guidance revisions, and constructive analyst sentiment suggest more dependable momentum than ALGN, which is contending with softening consumer demand and a recent wave of estimate and rating trims. That said, any such determination is probabilistic and depends on evolving market conditions rather than a fixed prediction of future returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALGN is a Hold and IDXX is a StrongBuy.
ALGN in upward trend: price rose above 50-day moving average on October 22, 2026
ALGN moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend. In 38 of 41 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on ALGN as a result. In 58 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for ALGN just turned positive on October 08, 2026. Looking at past instances where ALGN's MACD turned positive, the stock continued to rise in 27 of 42 cases over the following month. The odds of a continued upward trend are 64%.
Following a +3.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALGN advanced for three days, in 192 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
ALGN broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALGN entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating fairly steady price growth. ALGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.593) is normal, around the industry mean (4.989). P/E Ratio (26.778) is within average values for comparable stocks, (37.210). Projected Growth (PEG Ratio) (0.611) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.612) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 69 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
IDXX in +5.93% Uptrend, growing for three consecutive days on October 16, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where IDXX advanced for three days, in 174 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on IDXX as a result. In 55 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
The Moving Average Convergence Divergence (MACD) for IDXX just turned positive on September 22, 2026. Looking at past instances where IDXX's MACD turned positive, the stock continued to rise in 19 of 41 cases over the following month. The odds of a continued upward trend are 46%.
IDXX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IDXX crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 22 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 59%.
Bearish Trend Analysis
The 10-day RSI Indicator for IDXX moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 14 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 64%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDXX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
IDXX broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IDXX entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating fairly steady price growth. IDXX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (27.377) is normal, around the industry mean (65.617). P/E Ratio (39.160) is within average values for comparable stocks, (2.429). Projected Growth (PEG Ratio) (2.894) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (9.042) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDXX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
ALGN | IDXX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 65 Fair valued | 81 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 69 | 16 | |
PRICE GROWTH RATING 1..100 | 56 | 48 | |
P/E GROWTH RATING 1..100 | 23 | 73 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALGN's Valuation (65) in the Medical Specialties industry is in the same range as IDXX (81). This means that ALGN’s stock grew similarly to IDXX’s over the last 12 months.
ALGN's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as IDXX (100). This means that ALGN’s stock grew similarly to IDXX’s over the last 12 months.
IDXX's SMR Rating (16) in the Medical Specialties industry is somewhat better than the same rating for ALGN (69). This means that IDXX’s stock grew somewhat faster than ALGN’s over the last 12 months.
IDXX's Price Growth Rating (48) in the Medical Specialties industry is in the same range as ALGN (56). This means that IDXX’s stock grew similarly to ALGN’s over the last 12 months.
ALGN's P/E Growth Rating (23) in the Medical Specialties industry is somewhat better than the same rating for IDXX (73). This means that ALGN’s stock grew somewhat faster than IDXX’s over the last 12 months.
| ALGN | IDXX | |
|---|---|---|
| RSI ODDS (%) | N/A | 4 days ago 64% |
| Stochastic ODDS (%) | 4 days ago 70% | 4 days ago 71% |
| Momentum ODDS (%) | 4 days ago 73% | 4 days ago 59% |
| MACD ODDS (%) | 4 days ago 64% | 5 days ago 46% |
| TrendWeek ODDS (%) | 4 days ago 73% | 4 days ago 61% |
| TrendMonth ODDS (%) | 4 days ago 72% | 4 days ago 53% |
| Advances ODDS (%) | 5 days ago 70% | 11 days ago 60% |
| Declines ODDS (%) | 22 days ago 75% | 20 days ago 69% |
| BollingerBands ODDS (%) | 4 days ago 74% | 4 days ago 85% |
| Aroon ODDS (%) | 4 days ago 71% | 5 days ago 68% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALGN’s FA Score shows that 1 FA rating(s) are green while IDXX’s FA Score has 1 green FA rating(s).
- ALGN’s FA Score: 1 green, 4 red.
- IDXX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALGN’s TA Score shows that 4 TA indicator(s) are bullish while IDXX’s TA Score has 5 bullish TA indicator(s).
- ALGN’s TA Score: 4 bullish, 4 bearish.
- IDXX’s TA Score: 5 bullish, 5 bearish.
Price Growth
ALGN (@Pharmaceuticals: Other) experienced а +4.89% price change this week, while IDXX (@Medical Specialties) price change was +0.00% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +1.59%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +12.46%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +2.29%. For the same industry, the average monthly price growth was -8.06%, and the average quarterly price growth was +49.65%.
Reported Earning Dates
ALGN is expected to report earnings on Oct 28, 2026.
IDXX is expected to report earnings on Nov 02, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+1.59% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (+2.29% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement